Voloridge Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.82M | Buy |
+359,434
| New | +$1.82M | 0.01% | 962 |
|
|
2024
Q4 | – | Sell |
-973,583
| Closed | -$6.42M | – | 1348 |
|
|
2024
Q3 | $6.42M | Buy |
+973,583
| New | +$6.42M | 0.02% | 720 |
|
|
2024
Q2 | – | Sell |
-660,969
| Closed | -$6.59M | – | 1354 |
|
|
2024
Q1 | $6.59M | Buy |
660,969
+76,014
| +13% | +$758K | 0.02% | 578 |
|
|
2023
Q4 | $5.77M | Sell |
584,955
-269,440
| -32% | -$2.66M | 0.02% | 586 |
|
|
2023
Q3 | $6.54M | Buy |
+854,395
| New | +$6.54M | 0.03% | 576 |
|
|
2023
Q2 | – | Sell |
-50,834
| Closed | -$339K | – | 1536 |
|
|
2023
Q1 | $339K | Buy |
+50,834
| New | +$339K | ﹤0.01% | 1271 |
|
|
2022
Q3 | – | Sell |
-55,266
| Closed | -$450K | – | 1594 |
|
|
2022
Q2 | $450K | Sell |
55,266
-272,369
| -83% | -$2.22M | ﹤0.01% | 1309 |
|
|
2022
Q1 | $2.35M | Sell |
327,635
-50,082
| -13% | -$359K | 0.01% | 891 |
|
|
2021
Q4 | $6.47M | Buy |
+377,717
| New | +$6.47M | 0.04% | 623 |
|